Clinical trials · New York, NY
Sarcoma clinical trials in New York
We’re tracking 55 recruiting sarcoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05642455RecruitingPhase 1/Phase 2
Study of a new treatment for certain childhood cancers
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
New York, New YorkAges 2–21 - NCT07089992RecruitingPhase 2
Pembrolizumab for ultra-rare sarcoma types
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
New York, New YorkAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
New York, New YorkAges 18–90 - NCT07156565RecruitingPhase 1
Study of actinium therapy for advanced soft tissue sarcoma
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
New York, New YorkAges 18 years+ - NCT05672108RecruitingPhase 2
Chemo delivered into lung tumors using a catheter
This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.
New York, New YorkAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
New York, New YorkAges 16 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
New York, New YorkAges 6 months–25 years - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
New York, New YorkAges 18 years+ - NCT05918640RecruitingPhase 1/Phase 2
Lurbinectedin for cancers with specific EWS-related gene fusions
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
New York, New YorkAges 10 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
New York, New YorkAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
New York, New YorkAges 18 years+ - NCT07741877RecruitingPhase 2
Immune cells for advanced soft tissue sarcoma
This trial tests a treatment made from your own immune cells, called tumor-infiltrating lymphocytes, to see if they can shrink or slow down advanced soft tissue sarcoma. It might be an option if you have tried other treatments and your cancer is still growing.
New York, New YorkAges 16–70 - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
New York, New YorkAges 18 years+ - NCT04305691RecruitingPhase 2
Ixazomib for skin Kaposi sarcoma in people with HIV
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
New York, New YorkAges 18 years+ - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
New York, New YorkAges 12–85 - NCT05734066RecruitingPhase 1/Phase 2
Lurbinectedin drug study for young people with Ewing sarcoma
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
New York, New YorkAges 2–30 - NCT06797999RecruitingPhase 1/Phase 2
Study of ADCE-D01 for soft tissue sarcoma
This trial tests a new drug called ADCE-D01 for people with soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT06942442RecruitingPhase 2
Tebentafusp for advanced clear cell sarcoma
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
New York, New YorkAges 18 years+ - NCT07297979RecruitingPhase 1
Xaluritamig for relapsed or refractory Ewing sarcoma
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
New York, New YorkAges 2 years+ - NCT01109394Recruiting
Help study tumors with sample testing and a research biology library
This study collects tumor (or related) samples to analyze their genes and build a shared research “biobank.” It may help researchers understand cancers better for future diagnosis and treatments.
New York, New YorkAges 4 weeks+ - NCT00579566Recruiting
Research study using removed tissue from soft-tissue sarcoma
This study looks at tissue (samples taken during diagnosis or treatment) to learn new biological and molecular clues about soft-tissue sarcoma. Participating mainly helps researchers collect usable tissue that would otherwise be discarded.
New York, New YorkAges Any age - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
New York, New YorkAges 18 years+ - NCT06946225RecruitingPhase 1
Combination cell therapy for advanced melanoma or sarcoma
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
New York, New YorkAges 18 years+ - NCT06113315Enrolling by invitation
Collecting samples and data from sarcoma patients on immunotherapy
This study collects tissue samples and medical data from people with sarcoma who are receiving or will receive immunotherapy. Its goal is to learn more about how these treatments work against sarcoma.
New York, New YorkAges Any age
Hear when a new Sarcoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Sarcoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting sarcoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 19 studies
- Memorial Sloan Kettering Bergen · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Memorial Sloan Kettering Monmouth · 3 studies
- Memorial Sloan Kettering Westchester · 2 studies
- Columbia University Irving Medical Center
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital
What taking part in a sarcoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting sarcoma studies in New York.
Common questions
- Are there sarcoma clinical trials near New York?
- Yes. We're currently tracking 55 recruiting sarcoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a sarcoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a sarcoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New sarcoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.